Taken together, BAX and BAK deficiency in the DLD-1 colon cancer cells downregulated the expression of XPC and altered the energy metabolism of cancer cells via the upregulation of glycolysis implicating the development of drug resistance. Here, BAK1 is linked to malignant colon neoplasm.